- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01960530
Uno studio investigativo sull'idrocortisone
Uno studio in aperto, parzialmente randomizzato, monodose, crossover per valutare la farmacocinetica, la biodisponibilità orale e la relazione con i parametri metabolici di idrocortisone e Infacort® in volontari maschi adulti sani.
This study will investigate a new drug called Infacort®; a newly-developed immediate release formulation of a well-established drug called hydrocortisone. Hydrocortisone is used as a replacement treatment for people whose adrenal glands are not producing enough natural cortisol - a condition known as adrenal insufficiency. The study will assess how Infacort® acts once inside the body, by measuring cortisol and other hormone levels in the body, compared to already marketed hydrocortisone tablet and hydrocortisone intravenous (through the vein) injection.
The population who are eligible to take part in the study are healthy male volunteers, aged between 18 and 60 years of age.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
The study will evaluate the normal physiology, PK and metabolism of cortisol, investigate the PK and bioavailability of cortisol from the test Infacort® Granules (hydrocortisone) and the reference hydrocortisone tablets and i.v injection in healthy adult male volunteers and explore the role of cortisol in the regulation of metabolic pathways.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Merthyr Tydfil, Regno Unito, CF48 4DR
- Simbec Research Limited
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Healthy male volunteers between 18 and 60 years of age, inclusive (at screening).
-
Subjects with a Body Mass Index (BMI) of 21-28. Body Mass Index = Body weight (kg) / (Height (m))*2.
-
Subjects with no clinically significant abnormal serum biochemistry, haematology and urinalysis values within 14 days prior to Day 1 of Study Period 1.
-
Subjects with a negative urinary drugs of abuse screen, determined within 14 days prior to Day 1 of Study Period 1. A positive alcohol test may be repeated at the discretion of the Investigator.
-
Subjects with negative HIV and Hepatitis B and C results.
-
Subjects with no clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined within 14 days prior to Day 1 of Study Period 1.
-
Subjects with no clinically-significant deviation outside the normal ranges for blood pressure and pulse measurements.
-
Subjects (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) and sexual partners must use effective contraception methods during the trial and for 3 months after the last dose, for example:
- Oral contraceptive + condom
- Intra-uterine device (IUD) + condom
- Diaphragm with spermicide + condom
-
Subjects must be available to complete the study.
-
Subjects must satisfy a medical examiner about their fitness to participate in the study.
-
Subjects must provide written informed consent to participate in the study.
Exclusion Criteria:
- A clinically significant history of gastrointestinal disorder likely to influence drug absorption.
- Receipt of regular medication within 14 days prior to Day 1 of Study Period 1 (including high dose vitamins, dietary supplements or herbal remedies).
- Receipt of any vaccination within 14 days prior to Day 1 of Study Period 1.
- Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.
- Presence of clinically significant infections (systemic fungal and viral infections, acute bacterial infections).
- Current or previous history of tuberculosis.
- A clinically significant history of previous allergy / sensitivity to Hydrocortisone and/or Dexamethasone.
- A clinically significant history or family history of psychiatric disorders/illnesses.
- A clinically significant history of drug or alcohol abuse.
- Inability to communicate well with the Investigator (i.e., language problem, poor mental development or impaired cerebral function).
- Participation in a New Chemical Entity clinical study within the previous 4 months or a marketed drug clinical study within the previous 3 months. (N.B. The washout period between trials is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study)
- Subjects who have consumed more than 2 units of alcohol per day within seven (7) days prior to Day 1 of Study Period 1or have consumed any alcohol within the 48 hour period prior to Day 1 of Study Period 1.
- Donation of 450ml or more of blood within the previous 3 months.
- Subjects who smoke (or ex-smokers who have smoked within 6 months prior to Day 1 of Study Period 1).
- Subjects who work shifts (i.e. regularly alternate between days, afternoons and nights).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Nessun intervento: Endogenous Cortisol
No Study medication will be given during this study period, however various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. |
|
|
Altro: Dexamethasone
1mg Dexamethasone will be administered at 22:00 on Day 1 and at 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. Dexamethasone is considered a challenge agent and therefore a non-IMP |
Challenge agent
Altri nomi:
|
|
Sperimentale: Infacort®
20mg Infacort® will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous adrenocorticotropic Hormone (ACTH) and cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. |
Multi-particulate granules
Altri nomi:
|
|
Comparatore attivo: Hydrocortisone Tablet
20mg Hydrocortisone Tablet will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. |
Standard hydrocortisone tablets
Altri nomi:
|
|
Comparatore attivo: i.v Hydrocortisone Injection
20mg i.v. Hydrocortisone Injection will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. |
Standard hydrocortisone solution for intravenous injection
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Maximum Serum Concentration (Cmax)
Lasso di tempo: Hourly from 0 to 24 hours
|
Derived PK for Serum Cortisol: Maximum serum concentration (Cmax) |
Hourly from 0 to 24 hours
|
|
AUC0-t
Lasso di tempo: Hourly from 0 to 24 hours
|
Derived PK for Serum Cortisol: Area under the curve from 0-24 hours |
Hourly from 0 to 24 hours
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Adverse Events (AEs)
Lasso di tempo: Days 1-2 during each Study Period
|
Number of subjects with adverse events throughout the study. |
Days 1-2 during each Study Period
|
|
Concentrations of Cortisol Binding Protein
Lasso di tempo: Blood samples on Day 1 and/or Day 2 of each Study Period
|
Cortisol protein binding under physiological conditions and after the administration of dexamethasone and hydrocortisone. |
Blood samples on Day 1 and/or Day 2 of each Study Period
|
|
Insulin Sensitivity Under Physiological Conditions and After Administration of Dexamethasone and Infacort®, Hydrocortisone Tablets and i.v Hydrocortisone.
Lasso di tempo: Blood samples on Day 1 and/or Day 2 of each Study Period
|
A standardised mixed meal elevates blood glucose and provides a reproducible stimulation of insulin release. Lower levels of insulin secretion, whilst maintaining normoglycaemia would indicate enhanced insulin sensitivity and glucose disposal; higher insulin levels will reflect insulin resistance. |
Blood samples on Day 1 and/or Day 2 of each Study Period
|
|
PK and Metabolism of Cortisol
Lasso di tempo: Blood, urine & saliva samples on Day 1 and/or Day 2 of each Study Period
|
Blood: Serum cortisol under physiological conditions and after administration of dexamethasone and Infacort® Granules, Hydrocortisone Tablets and i.v Hydrocortisone Injection. |
Blood, urine & saliva samples on Day 1 and/or Day 2 of each Study Period
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Girish Sharma, Simbec Research
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stimato)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema endocrino
- Malattie della ghiandola surrenale
- Insufficienza surrenalica
- Ormoni
- Ormoni, sostituti ormonali e antagonisti ormonali
- Composti policiclici
- Incinta
- In gravidanza
- Steroidi
- Composti anelli fusi
- Steroidi, fluorurati
- Incintadienetrioli
- Gravideniones
- Incinta
- 11-idrossicosteroidi
- Idrossicorticosteroidi
- Ormoni della corteccia surrenale
- 17-idrossicosteroidi
- Desametasone
- Idrocortisone
Altri numeri di identificazione dello studio
- Infacort 002
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .